In vitro susceptibility of mycobacterium bovis against moxifloxacin Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
In-vitro and in-vivo activity of rifampicin and rifabutin against multi-drug-resistant strains of mycobacterium tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001
In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis Source: Eur Respir J 2014; 44: 808-811 Year: 2014
Characterization of drug susceptibility of nontuberculous mycobacteria of M.chelonae and M.fortuitum complexes. Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018
Express-diagnosing of multidrug resistant bacterial and L-forms of mycobacterium tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 721s Year: 2004
Characteristics of drug susceptibility testing for bedaquline and clofazimine of 178 drug-resistant Mycobacterium tuberculosis isolates in Japan Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019
Evaluation of a molecular assay for detection of rifampin and isoniazid resistant mycobacterium tuberculosis in strains and clinical samples Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
In vitro susceptibility testing of bedaquiline against mycobacteria avium-intracellulare complex Source: Virtual Congress 2020 – Aspergillosis and chronic lung infections Year: 2020
Amikacin exposure and susceptibility of macrolide-resistant Mycobacterium abscessus Source: ERJ Open Res, 5 (2) 00154-2018; 10.1183/23120541.00154-2018 Year: 2019
In vitro activity of moxifloxacin and linezolid against mycobacteriaSource: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Bedaquiline in the treatment of multi-drug resistant non-tuberculous mycobacteria soft tissue infections: a case series Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease Year: 2021
MIC and gyrA/B genetic analyses of fluoroquinolones against mycobacterium tuberculosis isolated in Japan Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Relationship between rpoB mutations and minimum inhibitory concentrations of rifampicin in multi drug resistant strains of mycobacterium tuberculosis Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011
Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
In vitro susceptibility testing and totally drug-resistant tuberculosis Source: Eur Respir J 2013; 42: 292 Year: 2013
In vitro susceptibility testing and totally drug-resistant tuberculosis Source: Eur Respir J 2013; 42: 291-292 Year: 2013
Resistance genotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Serbia Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019